News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Institute for Clinical Excellence (NICE) Rejects Sanofi (France) (SASY.PA)'s Cancer Drug Jevtana


9/30/2011 8:18:52 AM

Sanofi's prostate cancer drug Jevtana is not worth using on Britain's state health service, given its limited ability to extend life, its side effects and its cost, the healthcare watchdog NICE said on Friday. The draft guidance from the National Institute for Health and Clinical Excellence (NICE) is now open for consultation before further decisions on the medicine are made. Jevtana has been licensed for use in both Europe and the United States after clinical trials showed it helped men with advanced prostate cancer when given alongside the anti-inflammatory drug prednisone.

Read at Reuters
Read at BusinessWeek
Read at News Release
Read at InPharm.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES